Skip to main content
Caplight Logo









MediLink Therapeutics

MediLink Therapeutics

Private
SuzhouHealthcare & Life Scienceshttps://medilinkthera.com/

Last Round

Series B

Mar 14, 2022

Total Funding Raised

$120M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

MediLink Therapeutics is a biopharmaceutical company that develops innovative antibody-drug conjugates (ADC) for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADConcology therapeuticslinker-payload technologycancer drug developmentbiotech licensingclinical-stage biotechtargeted cancer therapybiopharma partnershipcytotoxic payloaddrug discovery platformprecision medicinenext-gen ADCsbiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MediLink Therapeutics Comparables

Compare MediLink Therapeutics with similar companies based on industry and business-model similarity.

MediLink Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Duality Biotherapeutics Inc
93%
Aimed Bio Inc.
82%
LigaChem Biosciences
79%

MediLink Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 14, 2022
Series AMar 1, 2021

MediLink Therapeutics Investors

Notable investors and investment history

MediLink Therapeutics investors
InvestorRounds
HighLight CapitalSeries B
Loyal Valley CapitalSeries B, Series A
Highlight CapitalSeries B
LYFE CapitalSeries B
Legend CapitalSeries B
Qiming Venture PartnersSeries B, Series A
Panacea Venture HealthcareSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors increased 76% MoM.

  • Jul 1, 2025

    Dr. Weichang Zhou appointed as new CTO.

Recent news

Latest coverage and updates

  • is_developingJul 15, 2026

    Medilinkthera is developing antibody-drug conjugate YL201 on Jul 15th '26.

MediLink Therapeutics Filings

Explore SEC and related filing metadata, where available.

MediLink Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MediLink Therapeutics's valuation, stock price, and market status.

Is MediLink a public or private company?

MediLink is a private company.

What is the current stock price of MediLink?

MediLink is a private company with no public stock price. No recent secondary market data is available.

How much is MediLink worth (valuation)?

Valuation information for MediLink is not publicly available.

Can I buy MediLink stock?

MediLink shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MediLink's last funding round?

MediLink's most recent funding round was Series B on March 14, 2022.

Who are the main investors in MediLink?

Key investors in MediLink include Loyal Valley Capital, LYFE Capital, Qiming Venture Partners, Apricot Capital.

Will MediLink IPO soon?

No public IPO plans have been announced for MediLink.

How can I track MediLink secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MediLink's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSuzhou
Employee Range65
Year Founded2020
Last FundingMar 14, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?